Clinical Trial Update: Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is recruiting to evaluate CLDN18.2/HER2-targeted CAR-NK cells for advanced gastric cancer and advanced gastroesophageal junction aden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• CLDN18.2/HER2 CAR-NK cells

Snippet

Sponsor: Beijing Biotech | Conditions: Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING